Literature DB >> 15827339

Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment.

Craig D Woodworth1, Evan Michael, Dan Marker, Sarah Allen, Laura Smith, Matthias Nees.   

Abstract

The epidermal growth factor receptor (EGFR) is overexpressed in several types of human cancer, and inhibition of EGFR function is a promising strategy for cancer therapy. We used cDNA microarrays to examine alterations in gene expression after treatment of carcinoma cells with PD153035, a specific and reversible inhibitor of EGFR function. When human cervical carcinoma cells were grown on a collagen substrate in three-dimensional organotypic culture, untreated cells expressed high levels of EGFR RNA and invaded the underlying collagen. Blocking EGFR function decreased DNA synthesis and inhibited invasion in a dose-dependent manner. Microarray analyses identified 312 genes that were significantly increased or decreased in expression after EGFR inhibition. Many could be classified into one of four functional groups including genes that (a) stimulate inflammation and innate immunity, (b) promote cell attachment, (c) enhance apoptosis, and (d) inhibit cell cycle progression. PD153035 induced a dose-dependent activation of nuclear factor kappaB, a transcription factor that stimulates proinflammatory gene expression. Our results identify alterations in gene expression caused by EGFR inhibition and show that this response varies significantly in different cell lines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827339     DOI: 10.1158/1535-7163.MCT-04-0238

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  35 in total

1.  Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.

Authors:  Viswanath Reddy Belum; Courtney Washington; Christine A Pratilas; Vincent Sibaud; Franck Boralevi; Mario E Lacouture
Journal:  Pediatr Blood Cancer       Date:  2015-02-12       Impact factor: 3.167

2.  Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.

Authors:  Craig D Woodworth; Laura P Diefendorf; David F Jette; Abdulmajid Mohammed; Michael A Moses; Sylvia A Searleman; Dan A Stevens; Katelynn M Wilton; Sumona Mondal
Journal:  Virology       Date:  2011-10-05       Impact factor: 3.616

3.  RNA interference against hepatic epidermal growth factor receptor has suppressive effects on liver regeneration in rats.

Authors:  Shirish Paranjpe; William C Bowen; George C Tseng; Jian-Hua Luo; Anne Orr; George K Michalopoulos
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

4.  Establishment and optimization of epithelial cell cultures from human ectocervix, transformation zone, and endocervix optimization of epithelial cell cultures.

Authors:  Han Deng; Sumona Mondal; Shantanu Sur; Craig D Woodworth
Journal:  J Cell Physiol       Date:  2019-01-04       Impact factor: 6.384

5.  The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity.

Authors:  Didem Tastekin; Makbule Tambas; Kemal Kilic; Kayhan Erturk; Deniz Arslan
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

6.  The role of VIP in cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Megan E Foldenauer; Linda D Hazlett
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-07       Impact factor: 4.799

Review 7.  Skin toxicities associated with epidermal growth factor receptor inhibitors.

Authors:  Tianhong Li; Roman Perez-Soler
Journal:  Target Oncol       Date:  2009-05-19       Impact factor: 4.493

Review 8.  Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.

Authors:  Cara M Martin; Louise Kehoe; Cathy O Spillane; John J O'Leary
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin.

Authors:  Saveria Pastore; Francesca Mascia
Journal:  Expert Rev Dermatol       Date:  2008-10

10.  Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

Authors:  B Melosky; R Burkes; D Rayson; T Alcindor; N Shear; M Lacouture
Journal:  Curr Oncol       Date:  2009-01       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.